Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?
Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.
Pharma & Biotech